Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension
| Autor: | Jeffrey R. Fineman, Elizabeth Colglazier, Hythem Nawaytou, Angelica J Ng, Claire Parker |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty business.industry digestive oral and skin physiology Inpatient setting 030204 cardiovascular system & hematology Selexipag medicine.disease Pulmonary hypertension Clinical Vignette 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 030228 respiratory system chemistry Tolerability Pediatrics Perinatology and Child Health Medicine Pharmacology (medical) business Adverse effect Treprostinil medicine.drug |
| Zdroj: | J Pediatr Pharmacol Ther |
| ISSN: | 1551-6776 |
| Popis: | There is limited published experience with transitioning pediatric patients from parenteral treprostinil to oral selexipag therapy. In addition, published transitions have typically been protracted, taking several weeks to complete. We present a case series of 3 adolescent patients who were transitioned from parenteral treprostinil to oral selexipag over a 5- to 7-day period. Their clinical courses leading up to the transitions are summarized and their outcomes are described. The 3 patients were successfully rapidly transitioned during an inpatient hospitalization without any observed adverse events or prostacyclin-related side effects. We conclude that when indicated rapid transition of parenteral to oral prostacyclin therapy may be performed safely in adolescents in an inpatient setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|